adavosertib + gemcitabine

**Adavosertib + gemcitabine** is a combination regimen consisting of adavosertib, a Wee1 kinase inhibitor (also known as AZD1775 or MK1775), and gemcitabine, an antimetabolite chemotherapeutic. This combination has shown synergistic anti-tumor activity, particularly in platinum-resistant or platinum-refractory recurrent high-grade serous ovarian cancer. Adavosertib inhibits the G2/M cell cycle checkpoint, promoting mitotic entry and cell death in cancer cells with DNA damage, especially those with TP53 mutations. Gemcitabine inhibits DNA synthesis during the S phase by incorporation into DNA and blocking further replication. Clinical studies indicate improved progression-free and overall survival in this ovarian cancer population versus gemcitabine alone, with increased hematological toxicity as a notable risk. The regimen is being developed primarily for ovarian cancer and its rare subtypes[1][3][5][7].

Brand names

adavosertib + gemcitabine

Other names

adavosertib + gemcitabine